Actively Recruiting
Effect of Fan Application in Preventing Ticagrelor-associated Dyspnea in Patients With Acute Coronary Syndrome
Led by Acibadem University · Updated on 2025-12-08
110
Participants Needed
2
Research Sites
2 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the effect of hand fan therapy on dyspnea (shortness of breath) associated with ticagrelor use in patients with acute coronary syndrome in a coronary intensive care unit. The study will compare standard care alone to standard care combined with hand fan therapy to see if the fan helps reduce breathing difficulties. This randomized trial will include 110 participants aged 18 to 65 who are starting ticagrelor treatment for the first time. Participants will be randomly assigned to either receive routine ward care including semi-Fowler positioning and breathing exercises or the same care plus hand fan therapy. The fan will be directed toward the patient's face for 5 minutes at 30, 60, and 120 minutes after ticagrelor administration. The study will record the presence, number, and severity of dyspnea episodes during the first two hours after medication. Throughout the study, researchers will monitor breathing status closely and record the incidence and timing of dyspnea attacks at baseline and at 30, 60, and 120 minutes post-treatment. Data will be analyzed by a separate statistician. Participants can expect assessments of their breathing and overall condition during this short observation period, with safety and symptom monitoring until the study ends.
CONDITIONS
Brief Title
Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Between the ages of 18 and 65
- No severe hearing and vision problems
- Can speak and understand Turkish
- Able to communicate easily
- First-time diagnosis of acute coronary syndrome
- Decided to start ticagrelor therapy
- Able to adapt to treatment
- Volunteered to participate in the research
You will not qualify if you...
- Problems preventing cognitive, emotional, or verbal communication
- Obstructive sleep abnormalities
- Diseases affecting respiratory function such as stage IV cancer, bronchial asthma, COVID-19, lung cancer, pulmonary edema, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary embolism, pneumonia, or bronchitis
- Metabolic abnormalities
- Intubated after procedure
- Previous treatment with ticagrelor
- Not volunteering to participate
- Loss to follow-up
- Voluntary withdrawal from the study
- Oxygen saturation below 95%
- Cardiac arrest
- Unable to fulfill study requirements
- Life-threatening conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - 2 hours after ticagrelor administration
Participants receive either standard ward care or standard care plus hand fan therapy after ticagrelor administration. Dyspnea presence, number, and severity are recorded during this period.
1 treatment period with assessments at baseline, 30, 60, and 120 minutes
Trial Site Locations
Total: 2 locations
1
İstanbul Üniversitesi-Cerrahapaşa
Istanbul, Avcılar, Turkey (Türkiye), 34320
Not Yet Recruiting
2
Sağlık Bilimleri Üniversitesi Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Eğitim Araştırma Hastanesi
Istanbul, Üsküdar, Turkey (Türkiye), 34668
Actively Recruiting
Research Team
E
Emine Tuğba YORULMAZ, research assistant
A
Arzu ERKOÇ, Associate professor
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here